Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8794933 | Ophthalmology Retina | 2017 | 7 Pages |
Abstract
In nonnaïve patients with active exudative AMD, treatment with a fixed intravitreal aflibercept dosing regimen for 24 months demonstrated sustained improvements in anatomy and vision in patients transitioned from other anti-vascular endothelial growth factor agents and stability when compared with 12-month outcomes. Patients who benefited most were those with worse vision at entry and longer duration of disease.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Fabiana Q. MD, Sunil MD, Justis P. MD, Ang MD, Rumneek BA, Andrew P. MD, Rishi P. MD,